IP Library › Granted Patent US 9,395,369

Granted Patent B2

US 9,395,369 · App. 14/059,309 · Granted Jul 19, 2016

Guinea pig cytomegalovirus (CIDMTR strain)

Inventor: Mark Schleiss (St. Paul, MN)

Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA

G01N33/56994 C12N7/00 A61K39/00 C12N2710/16121 G01N2500/00

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 9,395,369
App. No.: 14/059,309
Granted: Jul 19, 2016
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present disclosure provides an isolated or purified guinea pig cytomegalovirus (GPCMV) Strain CIDMTR, glycoproteins from GPCMV Strain CIDMTR, and methods of use thereof.

Claims (60)

1. A method for testing the effectiveness of a vaccine or therapeutic composition in preventing or ameliorating re-infection with cytomegalovirus comprising:

a. administering a first guinea pig cytomegalovirus (GPCMV) to a guinea pig,

b. administering a vaccine or therapeutic composition, and

c. administering a second GPCMV to the guinea pig,

wherein the first GPCMV is strain ATCC/22122 and the second GPCMV is strain CIDMTR or wherein the first GPCMV is strain CIDMTR and the second GPCMV is strain ATCC/22122; and

wherein

(a) the CIDMTR strain is ATCC® deposit number PTA-120714;

(b) the CIDMTR strain has at least 99% identity to SEQ ID NO:1;

(c) the CIDMTR Strain comprises 1) a glycoprotein (GP) having greater than 94% sequence identity to GPCMV glycoprotein 131 (GP131) (SEQ ID NO:3); and 2) a GP having greater than 84% sequence identity to GPCMV glycoprotein 129 (GP129) (SEQ ID NO:2), greater than 78% sequence identity to GP74 (gO) (SEQ ID NO:4), greater than 99% sequence identity to glycoprotein 55 (gB) (SEQ ID NO:6), greater than 93% sequence identity to glycoprotein 73 (gN) (SEQ ID NO: 7), greater than 99% sequence identity to glycoprotein 115 (gL) (SEQ ID NO:8), or greater than 82% sequence identity to GP75 (gH) (SEQ ID NO:5);

(d) the CIDMTR Strain comprises open reading frame gp147.1;

(e) the CIDMTR Strain comprises 1) a glycoprotein (GP) having greater than 93% sequence identity to glycoprotein 73 (gN) (SEQ ID NO: 7); and 2) a GP having greater than 84% sequence identity to GPCMV glycoprotein 129 (GP129) (SEQ ID NO:2), greater than 94% sequence identity to GPCMV glycoprotein 131 (GP131) (SEQ ID NO:3), greater than 78% sequence identity to GP74 (gO) (SEQ ID NO:4), greater than 99% sequence identity to glycoprotein 55 (gB) (SEQ ID NO:6), greater than 99% sequence identity to glycoprotein 115 (gL) (SEQ ID NO:8), or greater than 82% sequence identity to GP75 (gH) (SEQ ID NO:5); or

(f) the CIDMTR Strain comprises 1) a glycoprotein (GP) having greater than 99% sequence identity to glycoprotein 115 (gL) (SEQ ID NO:8); and 2) a GP having greater than 84% sequence identity to GPCMV glycoprotein 129 (GP129) (SEQ ID NO:2), greater than 94% sequence identity to GPCMV glycoprotein 131 (GP131) (SEQ ID NO:3), greater than 78% sequence identity to GP74 (gO) (SEQ ID NO:4), greater than 99% sequence identity to glycoprotein 55 (gB) (SEQ ID NO:6), greater than 93% sequence identity to glycoprotein 73 (gN) (SEQ ID NO: 7) or greater than 82% sequence identity to GP75 (gH) (SEQ ID NO:5).

2. The method of claim 1 , wherein

(i) the first GPCMV is strain ATCC/22122, and

(ii) the second GPCMV is strain CIDMTR.

3. The method of claim 1 , wherein

(i) the first GPCMV is strain CIDMTR, and

(ii) the second GPCMV is strain ATCC/22122.

4. The method of claim 1 , wherein (a) the CIDMTR strain is ATCC® deposit number PTA-120714.

5. The method of claim 1 , wherein (b) the CIDMTR strain has at least 99% identity to SEQ ID NO:1.

6. The method of claim 1 , wherein (c) the CIDMTR Strain comprises 1)a glycoprotein (GP) having greater than 94% sequence identity to GPCMV glycoprotein 131 (GP131) (SEQ ID NO:3); and 2) a GP having greater than 84% sequence identity to GPCMV glycoprotein 129 (GP129) (SEQ ID NO:2), greater than 78% sequence identity to GP74 (gO) (SEQ ID NO:4), greater than 99% sequence identity to glycoprotein 55 (gB) (SEQ ID NO:6), greater than 93% sequence identity to glycoprotein 73 (gN) (SEQ ID NO: 7), greater than 99% sequence identity to glycoprotein 115 (gL) (SEQ ID NO:8), or greater than 82% sequence identity to GP75 (gH) (SEQ ID NO:5).

7. The method of claim 1 , wherein (d) the CIDMTR Strain comprises open reading frame gp147.1.

8. The method of claim 1 , wherein (e) the CIDMTR Strain comprises 1) a glycoprotein (GP) having greater than 93% sequence identity to glycoprotein 73 (gN) (SEQ ID NO: 7); and 2) a GP having greater than 84% sequence identity to GPCMV glycoprotein 129 (GP129) (SEQ ID NO:2), greater than 94% sequence identity to GPCMV glycoprotein 131 (GP131) (SEQ ID NO:3), greater than 78% sequence identity to GP74 (gO) (SEQ ID NO:4), greater than 99% sequence identity to glycoprotein 55 (gB) (SEQ ID NO:6), greater than 99% sequence identity to glycoprotein 115 (gL) (SEQ ID NO:8), or greater than 82% sequence identity to GP75 (gH) (SEQ ID NO:5).

9. The method of claim 1 , wherein (f) the CIDMTR Strain comprises 1) a glycoprotein (GP) having greater than 99% sequence identity to glycoprotein 115 (gL) (SEQ ID NO:8); and 2) a GP having greater than 84% sequence identity to GPCMV glycoprotein 129 (GP129) (SEQ ID NO:2), greater than 94% sequence identity to GPCMV glycoprotein 131 (GP131) (SEQ ID NO:3), greater than 78% sequence identity to GP74 (gO) (SEQ ID NO:4), greater than 99% sequence identity to glycoprotein 55 (gB) (SEQ ID NO:6), greater than 93% sequence identity to glycoprotein 73 (gN) (SEQ ID NO: 7) or greater than 82% sequence identity to GP75 (gH) (SEQ ID NO:5).

10. A method for testing the effectiveness of a vaccine or therapeutic composition in preventing or ameliorating infection with cytomegalovirus comprising:

a. administering a vaccine or therapeutic composition to a guinea pig, and

b. administering a GPCMV strain CIDMTR to the guinea pig, wherein

(a) the CIDMTR strain is ATCC® deposit number PTA-120714;

(b) the CIDMTR strain has at least 99% identity to SEQ ID NO:1;

(c) the CIDMTR Strain comprises 1)a glycoprotein (GP) having greater than 94% sequence identity to GPCMV glycoprotein 131 (GP131) (SEQ ID NO:3); and 2) a GP having greater than 84% sequence identity to GPCMV glycoprotein 129 (GP129) (SEQ ID NO:2), greater than 78% sequence identity to GP74 (gO) (SEQ ID NO:4), greater than 99% sequence identity to glycoprotein 55 (gB) (SEQ ID NO:6), greater than 93% sequence identity to glycoprotein 73 (gN) (SEQ ID NO: 7), greater than 99% sequence identity to glycoprotein 115 (gL) (SEQ ID NO:8), or greater than 82% sequence identity to GP75 (gH) (SEQ ID NO:5);

(d) the CIDMTR Strain comprises open reading frame gp147.1;

11. The method of claim 10 , wherein the guinea pig is seronegative for GPCMV.

12. The method of claim 10 , wherein the guinea pig is seropositive for GPCMV.

13. The method of claim 12 , wherein the GPCMV infection is not ATCC/22122.

14. The method of claim 10 , wherein the vaccine, therapeutic composition or virus is administered via intramuscular, intradermal, subcutaneous delivery, or via a mucosal surface.

15. The method of claim 14 , wherein the administration is via mucosal surface, and the mucosal surface is an oral, intranasal, or intravaginal surface.

16. The method of claim 10 , wherein (a) the CIDMTR strain is ATCC® deposit number PTA-120714.

17. The method of claim 10 , wherein (b) the CIDMTR strain has at least 99% identity to SEQ ID NO:1.

18. The method of claim 10 , wherein (c) the CIDMTR Strain comprises 1) a glycoprotein (GP) having greater than 94% sequence identity to GPCMV glycoprotein 131 (GP131) (SEQ ID NO:3); and 2) a GP having greater than 84% sequence identity to GPCMV glycoprotein 129 (GP129) (SEQ ID NO:2), greater than 78% sequence identity to GP74 (gO) (SEQ ID NO:4), greater than 99% sequence identity to glycoprotein 55 (gB) (SEQ ID NO:6), greater than 93% sequence identity to glycoprotein 73 (gN) (SEQ ID NO: 7), greater than 99% sequence identity to glycoprotein 115 (gL) (SEQ ID NO:8), or greater than 82% sequence identity to GP75 (gH) (SEQ ID NO:5).

19. The method of claim 10 , wherein (d) the CIDMTR Strain comprises open reading frame gp147.1.

20. The method of claim 10 , wherein (e) the CIDMTR Strain comprises 1) a glycoprotein (GP) having greater than 93% sequence identity to glycoprotein 73 (gN) (SEQ ID NO: 7); and 2) a GP having greater than 84% sequence identity to GPCMV glycoprotein 129 (GP129) (SEQ ID NO:2), greater than 94% sequence identity to GPCMV glycoprotein 131 (GP131) (SEQ ID NO:3), greater than 78% sequence identity to GP74 (gO) (SEQ ID NO:4), greater than 99% sequence identity to glycoprotein 55 (gB) (SEQ ID NO:6), greater than 99% sequence identity to glycoprotein 115 (gL) (SEQ ID NO:8), or greater than 82% sequence identity to GP75 (gH) (SEQ ID NO:5).

21. The method of claim 10 , wherein (f) the CIDMTR Strain comprises 1) a glycoprotein (GP) having greater than 99% sequence identity to glycoprotein 115 (gL) (SEQ ID NO:8); and 2) a GP having greater than 84% sequence identity to GPCMV glycoprotein 129 (GP129) (SEQ ID NO:2), greater than 94% sequence identity to GPCMV glycoprotein 131 (GP131) (SEQ ID NO:3), greater than 78% sequence identity to GP74 (gO) (SEQ ID NO:4), greater than 99% sequence identity to glycoprotein 55 (gB) (SEQ ID NO:6), greater than 93% sequence identity to glycoprotein 73 (gN) (SEQ ID NO: 7) or greater than 82% sequence identity to GP75 (gH) (SEQ ID NO:5).

22. A method for testing the effectiveness of a vaccine or therapeutic composition in preventing or ameliorating infection with cytomegalovirus comprising:

a. administering a vaccine or therapeutic composition to a first guinea pig seronegative for GPCMV and to a second guinea pig seronegative for GPCMV, and

b. administering a GPCMV strain CIDMTR to the first guinea pig and GPCMV strain ATCC/22122 to the second guinea pig, wherein

(a) the CIDMTR strain is ATCC® deposit number PTA-120714;

(b) the CIDMTR strain has at least 99% identity to SEQ ID NO:1;

(c) the CIDMTR Strain comprises 1)a glycoprotein (GP) having greater than 94% sequence identity to GPCMV glycoprotein 131 (GP131) (SEQ ID NO:3); and 2) a GP having greater than 84% sequence identity to GPCMV glycoprotein 129 (GP129) (SEQ ID NO:2), greater than 78% sequence identity to GP74 (gO) (SEQ ID NO:4), greater than 99% sequence identity to glycoprotein 55 (gB) (SEQ ID NO:6), greater than 93% sequence identity to glycoprotein 73 (gN) (SEQ ID NO: 7), greater than 99% sequence identity to glycoprotein 115 (gL) (SEQ ID NO:8), or greater than 82% sequence identity to GP75 (gH) (SEQ ID NO:5);

(d) the CIDMTR Strain comprises open reading frame gp147.1;

23. The method of claim 22 , wherein the vaccine, therapeutic composition or virus is administered via intramuscular, intradermal, subcutaneous delivery, or via a mucosal surface.

24. The method of claim 22 , wherein (a) the CIDMTR strain is ATCC® deposit number PTA-120714.

25. The method of claim 22 , wherein (b) the CIDMTR strain has at least 99% identity to SEQ ID NO:1.

26. The method of claim 22 , wherein (c) the CIDMTR Strain comprises 1) a glycoprotein (GP) having greater than 94% sequence identity to GPCMV glycoprotein 131 (GP131) (SEQ ID NO:3); and 2) a GP having greater than 84% sequence identity to GPCMV glycoprotein 129 (GP129) (SEQ ID NO:2), greater than 78% sequence identity to GP74 (gO) (SEQ ID NO:4), greater than 99% sequence identity to glycoprotein 55 (gB) (SEQ ID NO:6), greater than 93% sequence identity to glycoprotein 73 (gN) (SEQ ID NO: 7), greater than 99% sequence identity to glycoprotein 115 (gL) (SEQ ID NO:8), or greater than 82% sequence identity to GP75 (gH) (SEQ ID NO:5).

27. The method of claim 22 , wherein (d) the CIDMTR Strain comprises open reading frame gp147.1.

28. The method of claim 22 , wherein (e) the CIDMTR Strain comprises 1) a glycoprotein (GP) having greater than 93% sequence identity to glycoprotein 73 (gN) (SEQ ID NO: 7); and 2) a GP having greater than 84% sequence identity to GPCMV glycoprotein 129 (GP129) (SEQ ID NO:2), greater than 94% sequence identity to GPCMV glycoprotein 131 (GP131) (SEQ ID NO:3), greater than 78% sequence identity to GP74 (gO) (SEQ ID NO:4), greater than 99% sequence identity to glycoprotein 55 (gB) (SEQ ID NO:6), greater than 99% sequence identity to glycoprotein 115 (gL) (SEQ ID NO:8), or greater than 82% sequence identity to GP75 (gH) (SEQ ID NO:5).

29. The method of claim 22 , wherein (f) the CIDMTR Strain comprises 1) a glycoprotein (GP) having greater than 99% sequence identity to glycoprotein 115 (gL) (SEQ ID NO:8); and 2) a GP having greater than 84% sequence identity to GPCMV glycoprotein 129 (GP129) (SEQ ID NO:2), greater than 94% sequence identity to GPCMV glycoprotein 131 (GP131) (SEQ ID NO:3), greater than 78% sequence identity to GP74 (gO) (SEQ ID NO:4), greater than 99% sequence identity to glycoprotein 55 (gB) (SEQ ID NO:6), greater than 93% sequence identity to glycoprotein 73 (gN) (SEQ ID NO: 7) or greater than 82% sequence identity to GP75 (gH) (SEQ ID NO:5).

Assignments (2)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2014

From: SCHLEISS, MARK

To: REGENTS OF THE UNIVERSITY OF MINNESOTA

Reel/Frame 032740/0335 →

CONFIRMATORY LICENSE Recorded Nov 20, 2013

From: REGENTS OF THE UNIVERSITY OF MINNESOTA

To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT

Reel/Frame 031690/0858 →

Continuity (2)

Provisional Application 61716302 · Oct 19, 2012

Related Publication 20140127265A1 · May 8, 2014